Implants with controlled drug delivery features and methods of using same
AssigneeDose Medical Corporation
InventorsDavid S. Haffner, Thomas W. Burns, Harold A. Heitzmann, Kenneth M. Curry
Life of this patent
Estimating the term…
Abstract
Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Claims23
A drug delivery ocular implant comprising:
- an outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior space;
- at least a first therapeutic agent disposed within said interior space;
- a cap positioned on the proximal end of said outer shell,
- wherein said cap comprises at least one aperture;
- and
- a permeable or semi-permeable material positioned between said cap and said proximal end of said outer shell,
- wherein said permeable or semi-permeable material is permeable to said at least a first therapeutic agent,
- wherein said permeable or semi-permeable material is dimensioned based on the permeability of said permeable or semi-permeable material to said at least a first therapeutic agent, and
- wherein said permeable or semi-permeable material occludes said at least one aperture, thereby allowing elution of said at least a first therapeutic agent to occur only through said permeable or semi-permeable material;
- wherein said proximal end of said outer shell is configured to be positioned in an anterior chamber of an eye.
A drug delivery ocular implant comprising:
- an outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior space;
- at least a first therapeutic agent disposed within said interior space;
- a cap positioned on the proximal end of said outer shell,
- wherein said cap comprises at least one portion permeable or semi-permeable to said at least a first therapeutic agent,
- wherein said at least one permeable or semi-permeable portion is dimensioned based on the permeability of said at least one permeable or semi-permeable portion to said at least a first therapeutic agent,
- wherein upon placement of the cap over the proximal end of the outer shell, said cap extends towards said distal end of said outer shell and encloses a portion of said outer shell,
- wherein elution of said at least a first therapeutic agent occurs only through said at least one permeable or semi-permeable portion;
- and
- wherein said proximal end of said outer shell is configured to be positioned in an anterior chamber of an eye.
A drug delivery ocular implant comprising:
- an outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior space;
- at least a first therapeutic agent disposed within said interior space;
- a cap comprising at least one aperture and dimensioned for positioning over the proximal end of the outer shell, wherein the cap extends towards said distal end of said outer shell and encloses a portion of said outer shell,
- a first material through which the at least a therapeutic agent elutes positioned between said cap and said proximal end of said outer shell,
- wherein said first material is permeable or semi-permeable to said at least a first therapeutic agent and occludes said at least one aperture, thereby allowing elution of said at least a first therapeutic agent to occur only through said first material;
- and
- a retention protrusion comprising a sharpened element on the distal end of said outer shell,
- wherein said proximal end of said outer shell is configured to be positioned in an anterior chamber of an eye.
Dependencies are inferred from the claim text.